8 December 2016 in American Journal of Neuroradiology
BACKGROUND AND PURPOSE: The introduction of liquid embolic agents has revolutionized endovascular approach to cranial vascular malformations. The aim of the study was to retrospectively assess the efficacy and safety of Precipitating Hydrophobic Injectable Liquid (PHIL), a new nonadhesive liquid embolic agent, in the treatment of patients with cranial dural arteriovenous fistulas. The primary end point was the rate of complete occlusion of dural arteriovenous fistulas. Secondary end points included the incidence of adverse events and clinical status at 3-month follow-up. MATERIALS AND METHODS: This was a retrospective multicenter study. Twenty-six consecutive patients with dural arteriovenous fistulas (de novo or previously treated) treated by injection of PHIL only or with PHIL in combination with other embolization products (such as Onyx or detachable coils) were included in the study. Recruitment started in August 2014 and ended in September 2015. RESULTS: Twenty-two (85%) patients were treated with PHIL only, with 3 patients treated with both PHIL and Onyx, and 1, with both PHIL and coils. Immediate complete angiographic occlusion was achieved in 20 (77%) patients. Of the 6 patients with residual fistulas, 3 were retreated with PHIL and 1 achieved angiographic cure. An adverse event was seen in 1 patient who developed worsening of preexisting ataxia due to acute thrombosis of the draining vein. CONCLUSIONS: PHIL appears to be safe and effective for endovascular treatment of cranial dural arteriovenous fistulas. Short-term angiographic and clinical results are comparable with those of Onyx, with the added advantage of easier preparation and improved homogeneous cast visualization. The use of iodine as a radio-opacifier also produces considerably less artifacts on CT compared with tantalum-based embolic materials.
10 May 2017 in Journal of NeuroInterventional Surgery
Background Experience with the endovascular treatment of unruptured small intracranial aneurysms by flow diverter devices is still limited. Objective To assess the safety and efficacy of the SILK flow diverter (SFD) in the treatment of small unruptured cerebral aneurysms (<10 mm). Methods We performed a retrospective review of a prospectively maintained database of patients treated with a SFD between July 2008 and December 2013 at 4 institutions in Spain to identify all patients with small unruptured aneurysms (<10 mm). Data for patient demographics, aneurysm characteristics, and technical procedures were analyzed. Angiographic and clinical findings were recorded during the procedure and at 6- and 12-month follow-ups. Results A total of 109 small aneurysms were treated with a SFD in 104 patients (78 women; 26 men; mean, median, and range of age: 55.2, 57.1, and 19–80 years, respectively). A total of 60 patients were asymptomatic (57.7%). All except 7 aneurysms (6.4%) arose from the anterior circulation. The mean size of the aneurysms was 4.7±1.9 mm. At 6 months, the neuromorbidity and neuromortality rates were 2.9% and 0.9%, respectively. Imaging at the 12-month follow-up showed complete occlusion, neck remnants, and residual aneurysm in 88.5% (69/78), 7.7% (6/78), and 3.3% (3/78) of cases, respectively. No delayed hemorrhage occurred. Conclusions The findings suggest that the indications for SFD can be safely extended to small intracranial aneurysms.
1 October 2019 in International Journal of Pediatric Otorhinolaryngology
1 July 2026 in Neurointervention
Scalp arteriovenous fistulas (sAVFs) are rare vascular lesions that may cause cosmetic deformity, bruit, headache, and recurrence after incomplete treatment. We report a patient in their 30s with a recurrent left frontotemporal sAVF previously embolized with PHIL 25, who presented with progressive enlargement, audible bruit, and headache. Digital subtraction angiography demonstrated a high-flow fistula supplied by bilateral superficial temporal and ophthalmic artery branches. Direct-puncture embolization with 12 mL of ihtObtura 20 achieved complete angiographic occlusion without complications. Clinical and imaging follow-up at 3, 6, and 12 months showed durable symptom resolution, no recurrence, progressive loss of radiopacity, reduced imaging artifacts, absence of skin tattooing, and volume reduction of the treated mass. This case suggests that ihtObtura may be useful for selected superficial recurrent vascular lesions in which cosmesis, durable occlusion, and artifact-free follow-up imaging are clinically relevant.